Last reviewed · How we verify
NCT05772091: ATTR-AI
Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach
trial in Transthyretin Cardiac Amyloidosis in 1,000 participants. Status unknown.
31 March 2024
Quick facts
| Lead sponsor | Pr. Nicolas GIRERD |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 29 September 2023 |
| Primary completion | 31 March 2024 |
| Estimated completion | 31 March 2024 |
| Sites | 4 locations across France |
Conditions studied
- Transthyretin Cardiac Amyloidosis — all drugs for Transthyretin Cardiac Amyloidosis →
Sponsor
Pr. Nicolas GIRERD — full company profile →
Who can join
18 and older, any sex, with Transthyretin Cardiac Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved ejection fraction. Its diagnosis is currently based on a non-invasive method including biology and imaging. Still currently incurable, the evolution of this pathology is burdened by numerous comorbidities, including iterative hospitalizations for heart failure leading to death. The Machine Learning approach has already shown its efficiency in terms of diagnosis but its prognostic approach has not yet been studied.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05772091
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transthyretin Cardiac Amyloidosis
Currently open trials in the same condition.
- NCT05797857 — Exercise Training in Transthyretin Cardiac Amyloidosis · NA · recruiting
- NCT05489523 — Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic · Phase 4 · recruiting
Other Pr. Nicolas GIRERD trials
Trials by the same sponsor.
- NCT06509854 — PAthwAy of Dyspneic patIent in Emergency in France · not yet recruiting
- NCT06235008 — PAthwAy of Dyspneic patIent in Emergency in the North-east Region (North-East PArADIsE) · not yet recruiting
- NCT06256913 — Machine Learning Approach Based on Echocardiographic Data to Improve Prediction of Cardiovascular Events in Hypertrophic · unknown
- NCT05818280 — Relationship Between 24-hour Blood Pressure Variability and FRagility in the Elderly Patient · completed
- NCT05089162 — CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05772091 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pr. Nicolas GIRERD
- Last refreshed: 28 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05772091.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing